Daily Archives: February 5, 2022

Helicobacter pylori-induced RASAL2 through activation of NF-kB promotes gastric tumorigenesis via β-catenin signaling axis

Posted on February 5, 2022 by Gastroenterology Journal

Helicobacter pylori (H. pylori) infection is the predominant risk factor for gastric cancer. RAS protein activator like 2 (RASAL2) is considered a double-edged sword in carcinogenesis. Herein, we investigated the role of RASAL2 in response to H. pylori… Continue reading →

Posted in News | Comments Off on Helicobacter pylori-induced RASAL2 through activation of NF-kB promotes gastric tumorigenesis via β-catenin signaling axis

Guselkumab for the treatment of Crohn’s disease: Induction results from the Phase 2 GALAXI-1 study

Posted on February 5, 2022 by Gastroenterology Journal

Guselkumab, a selective p19 interleukin-23 antagonist, is approved for the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and safety of guselkumab in patients with moderately to severely active Crohn’s disease … Continue reading →

Posted in News | Comments Off on Guselkumab for the treatment of Crohn’s disease: Induction results from the Phase 2 GALAXI-1 study